We have delineated another downstream target of NF-κB, the cytokine/LPS-inducible form of nitric oxide synthase (iNOS), which may respond to NF-κB inhibitors as well and thereby modulate the radioresponse of tumour cells. The gene discussed is NFKB1; the disease is neoplasm.